Literature DB >> 15294451

Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: characterization by [125I]Ang IV binding and catalytic activity.

Heidi Demaegdt1, Patrick Vanderheyden, Jean-Paul De Backer, Sabrina Mosselmans, Hilde Laeremans, Minh Tam Le, Veerle Kersemans, Yvette Michotte, Georges Vauquelin.   

Abstract

The angiotensin II C-terminal hexapeptide fragment angiotensin IV (Ang IV) exerts central and cardiovascular effects. Cystinyl aminopeptidase (EC 3.4.11.3), a membrane-associated zinc-dependent metallopeptidase of the M1 family, has recently been found to display high affinity for Ang IV and it was proposed to represent the AT4 receptor. We present evidence for the presence of endogenous cystinyl aminopeptidase in membranes from Chinese hamster ovary (CHO-K1) cells by binding studies with [125I]Ang IV and by measuring the cleavage of L-leucine-p-nitroanilide. The equilibrium dissociation constant of [125I]Ang IV in saturation binding studies (KD= 0.90 nM) was similar to the value (KD= 0.70 nM) calculated from the association and dissociation rates. Binding was displaced with high potency by the "AT4 receptor" ligands (Ang IV > divalinal1-Ang IV approximately LVV-hemorphin-7 approximately LVV-hemorphin-6 > Ang (3-7) > Ang III > Ang (4-8)) but not by AT1/AT2 receptor antagonists. Enzymatic activity in CHO-K1 cell membranes was competitively inhibited upto 94% by Ang IV and other "AT4 receptor" ligands (Ang IV > Ang III approximately divalinal1-Ang IV approximately Ang (3-7) approximately LVV-hemorphin-7 > Ang (4-8) approximately LVV-hemorphin-6). High affinity binding of [125I]Ang IV required the presence of metal chelators and the ligands such as Ang IV and LVV-hemorphin-7 displayed higher potency in the binding studies as in the enzyme assay. This difference in potency varied from one peptide to another. These pharmacological properties match those previously reported for the recombinantly-expressed human cystinyl aminopeptidase in embryonal kidney cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294451     DOI: 10.1016/j.bcp.2004.05.047

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  9 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Metal ion modulation of cystinyl aminopeptidase.

Authors:  Hilde Laeremans; Heidi Demaegdt; Jean-Paul De Backer; Minh T Le; Veerle Kersemans; Yvette Michotte; Georges Vauquelin; Patrick M L Vanderheyden
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

Review 3.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

4.  Translocation of the insulin-regulated aminopeptidase to the cell surface: detection by radioligand binding.

Authors:  H Demaegdt; L Smitz; J-P De Backer; M T Le; M Bauwens; E Szemenyei; G Tóth; Y Michotte; P Vanderheyden; G Vauquelin
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

5.  Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.

Authors:  J Longden; E-L Cooke; S J Hill
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

6.  Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies.

Authors:  Jean K Ho; Daniel A Nation
Journal:  Neurosci Biobehav Rev       Date:  2018-05-04       Impact factor: 8.989

7.  Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides.

Authors:  Sanjay R Borhade; Ulrika Rosenström; Jonas Sävmarker; Thomas Lundbäck; Annika Jenmalm-Jensen; Kristmundur Sigmundsson; Hanna Axelsson; Fredrik Svensson; Vivek Konda; Christian Sköld; Mats Larhed; Mathias Hallberg
Journal:  ChemistryOpen       Date:  2014-11-21       Impact factor: 2.911

8.  27-Hydroxycholesterol impairs neuronal glucose uptake through an IRAP/GLUT4 system dysregulation.

Authors:  Muhammad-Al-Mustafa Ismail; Laura Mateos; Silvia Maioli; Paula Merino-Serrais; Zeina Ali; Maria Lodeiro; Eric Westman; Eran Leitersdorf; Balázs Gulyás; Lars Olof-Wahlund; Bengt Winblad; Irina Savitcheva; Ingemar Björkhem; Angel Cedazo-Mínguez
Journal:  J Exp Med       Date:  2017-02-17       Impact factor: 14.307

9.  Synthesis, Evaluation and Proposed Binding Pose of Substituted Spiro-Oxindole Dihydroquinazolinones as IRAP Inhibitors.

Authors:  Karin Engen; Sudarsana Reddy Vanga; Thomas Lundbäck; Faith Agalo; Vivek Konda; Annika Jenmalm Jensen; Johan Åqvist; Hugo Gutiérrez-de-Terán; Mathias Hallberg; Mats Larhed; Ulrika Rosenström
Journal:  ChemistryOpen       Date:  2020-03-02       Impact factor: 2.911

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.